Clinical Trials Browser

Thyroid Cancer, Papillary, Breast Neoplasms, Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Head and Neck Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Site, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Sarcoma, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Central Nervous System Neoplasms, Myofibromatosis, Carcinoma, Medullary

NCT02864992 2025-12-23

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Phase 2 Active not recruiting

337 enrolled 13 charts 2 FDA

Thoracic

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Neoplasms

NCT01743131 2025-12-11

Abatacept as GVHD Prophylaxis Phase 2

Phase 2 Completed

186 enrolled 14 charts 1 FDA

Graft vs Host Disease, Neoplasms

NCT03915951 2025-11-17

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Phase 2 Completed

98 enrolled 18 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms

NCT03470922 2025-09-09

RELATIVITY-047

Phase 2/3 Active not recruiting

714 enrolled 17 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT02684006 2025-07-30

JAVELIN Renal 101

Phase 3 Completed

886 enrolled 37 charts 1 FDA

Genitourinary

Carcinoma, Renal Cell, Kidney Diseases, Kidney Neoplasms, Neoplasms

NCT03037385 2025-05-31

ARROW

Phase 1/2 Completed

590 enrolled 58 charts 5 FDA

EndocrineGastrointestinalHead & NeckNETThoracic

Thyroid Cancer, Papillary, Adenocarcinoma, Adenocarcinoma, Papillary, Bronchial Neoplasms, Carcinoma, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, Colonic Diseases, Colonic Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Endocrine System Diseases, Endocrine Gland Neoplasms, Gastrointestinal Diseases, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Intestinal Diseases, Intestinal Neoplasms, Lung Diseases, Lung Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Germ Cell and Embryonal, Neoplasms, Glandular and Epithelial, Neoplasms, Nerve Tissue, Respiratory Tract Diseases, Respiratory Tract Neoplasms, Thoracic Neoplasms, Thyroid Diseases, Thyroid Neoplasms, Colorectal Neoplasms, Neuroectodermal Tumors, Carcinoma, Medullary, Carcinoma, Neuroendocrine, Neuroendocrine Tumors, Multiple Endocrine Neoplasia Type 2a

NCT02437318 2025-02-13

SOLAR-1

Phase 3 Completed

572 enrolled 22 charts 1 FDA

BreastEndocrine

Breast Neoplasms, Neoplasms, Multiple Endocrine Neoplasia Type 1

NCT01121588 2025-01-23

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 1 Terminated

44 enrolled 22 charts 1 FDA

CNSLymphoid

Lymphoma, Neoplasms, Neuroblastoma

NCT02393859 2024-05-29

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Phase 3 Completed

111 enrolled 23 charts 1 FDA

LymphoidOther hematologic neoplasm

Immunoproliferative Disorders, Lymphoproliferative Disorders, Neoplasms, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT02564900 2024-01-22

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

Phase 1 Completed

292 enrolled 35 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT02422615 2023-11-30

MONALEESA-3

Phase 3 Completed

726 enrolled 17 charts 1 FDA

BreastEndocrine

Breast Diseases, Breast Neoplasms, Neoplasms, Neoplasms by Site, Multiple Endocrine Neoplasia Type 1

NCT01682083 2023-08-30

COMBI-AD

Phase 3 Completed

870 enrolled 13 charts 1 FDA

Dermatologic

Melanoma, Neoplasms

NCT02034110 2023-08-21

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

Phase 2 Completed

206 enrolled 40 charts 2 FDA

CNSEndocrineGastrointestinalHead & NeckOther hematologic neoplasmPlasma cellSarcoma

Nonseminomatous germ cell tumor, Biliary Tract Neoplasms, Glioma, Leukemia, Hairy Cell, Multiple Myeloma, Neoplasms, Gastrointestinal Stromal Tumors, Thyroid Carcinoma, Anaplastic

NCT02501096 2023-07-20

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

Phase 1/2 Completed

357 enrolled 28 charts 1 FDA

Tumor-Agnostic

Neoplasms

NCT01761266 2022-04-05

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Phase 3 Completed

954 enrolled 19 charts 1 FDA

Gastrointestinal

Carcinoma, Hepatocellular, Neoplasms

NCT01336634 2022-04-04

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.

Phase 2 Completed

177 enrolled 19 charts 1 FDA

Thoracic

Carcinoma, Non-Small-Cell Lung, Neoplasms

Clinical Trials

COLUMBUS

Spotlight

GLOW

LIBRETTO-121

Tepotinib Phase II in NSCLC Harboring MET Alterations (VISION)

Abatacept as GVHD Prophylaxis Phase 2

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

RELATIVITY-047

JAVELIN Renal 101

ARROW

SOLAR-1

Studying An Investigational Drug Crizotinib (PF-02341066) In Non Non-Small Cell Lung Cancer Tumors That Are Positive For Anaplastic Lymphoma Kinase (ALK)

Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL)

Study of DS-8201a in Subjects With Advanced Solid Malignant Tumors

MONALEESA-3

COMBI-AD

Efficacy and Safety of the Combination Therapy of Dabrafenib and Trametinib in Subjects With BRAF V600E- Mutated Rare Cancers

A Trial of Lenvatinib (E7080) Plus Pembrolizumab in Participants With Selected Solid Tumors

A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma

Study of Selective BRAF Kinase Inhibitor Dabrafenib Monotherapy Twice Daily and in Combination With Dabrafenib Twice Daily and Trametinib Once Daily in Combination Therapy in Subjects With BRAF V600E Mutation Positive Metastatic (Stage IV) Non-small Cell Lung Cancer.